During the past decade, Sapporo City General Hospital conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Sapporo City General Hospital" are "Active Systemic Lupus Erythematosus" (1 trials), "Kidney Disease" (1 trials), "Systemic Lupus Erythematosus" (1 trials) and "Systemic Lupus Erythematosus (SLE)" (1 trials). Many other conditions were trialed in "Sapporo City General Hospital" in a lesser frequency.

Most popular intervention types in "Sapporo City General Hospital" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "BMS-986165" (1 trials), "Efavaleukin Alfa" (1 trials), "Mezagitamab" (1 trials), "Placebo" (1 trials) and "Placebo for Rozibafusp Alfa" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sapporo City General Hospital" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Sapporo City General Hospital". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Sapporo City General Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sapporo City General Hospital, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".